Rhumbline Advisers Cel Sci Corp Transaction History

Rhumbline Advisers

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$2.11 - $2.83 $2,574 - $3,452	1,220 New	1,220 $2,000
Q2 2022 Aug 11, 2022	SELL	$2.58 - $4.99 $100,044 - $193,497	-38,777 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$3.93 - $7.7 $1,992 - $3,903	-507 Reduced 1.29%	38,777 $152,000
Q4 2021 Feb 10, 2022	SELL	$7.1 - $12.82 $4,323 - $7,807	-609 Reduced 1.53%	39,284 $279,000
Q3 2021 Nov 12, 2021	BUY	$7.64 - $12.49 $10,482 - $17,136	1,372 Added 3.56%	39,893 $438,000
Q2 2021 Aug 05, 2021	SELL	$8.68 - $27.49 $37,228 - $117,904	-4,289 Reduced 10.02%	38,521 $334,000
Q1 2021 May 06, 2021	SELL	$12.0 - $27.64 $32,796 - $75,540	-2,733 Reduced 6.0%	42,810 $651,000
Q4 2020 Feb 10, 2021	BUY	$11.05 - $16.62 $31,404 - $47,234	2,842 Added 6.66%	45,543 $531,000
Q3 2020 Nov 12, 2020	SELL	$11.69 - $14.54 $62,225 - $77,396	-5,323 Reduced 11.08%	42,701 $544,000
Q2 2020 Aug 13, 2020	BUY	$9.75 - $17.6 $105,300 - $190,080	10,800 Added 29.01%	48,024 $717,000
Q1 2020 May 06, 2020	BUY	$7.54 - $17.05 $90,351 - $204,310	11,983 Added 47.47%	37,224 $430,000
Q4 2019 Feb 05, 2020	BUY	$6.71 - $9.55 $2,704 - $3,848	403 Added 1.62%	25,241 $231,000
Q3 2019 Oct 23, 2019	BUY	$6.0 - $9.6 $17,862 - $28,579	2,977 Added 13.62%	24,838 $222,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $82,415 - $189,534	21,861 New	21,861 $183,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.